Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.62 and traded as high as $5.05. Achieve Life Sciences shares last traded at $4.85, with a volume of 65,692 shares changing hands.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. Maxim Group lowered their price target on shares of Achieve Life Sciences from $21.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 16th. Oppenheimer lowered their price target on shares of Achieve Life Sciences from $27.00 to $20.00 in a report on Tuesday, November 15th.
Achieve Life Sciences Price Performance
The company has a current ratio of 3.03, a quick ratio of 3.03 and a debt-to-equity ratio of 15.10. The firm has a market cap of $86.82 million, a price-to-earnings ratio of -1.22 and a beta of 1.22. The company’s 50-day moving average is $3.17 and its 200-day moving average is $3.62.
Achieve Life Sciences (NASDAQ:ACHV – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.25). Equities research analysts predict that Achieve Life Sciences, Inc. will post -4.04 earnings per share for the current year.
Institutional Trading of Achieve Life Sciences
Several large investors have recently made changes to their positions in the company. Prelude Capital Management LLC acquired a new stake in Achieve Life Sciences in the second quarter valued at approximately $49,000. Charles Schwab Investment Management Inc. acquired a new stake in Achieve Life Sciences in the first quarter valued at approximately $79,000. Raymond James & Associates acquired a new stake in Achieve Life Sciences in the first quarter valued at approximately $99,000. Granite Point Capital Management L.P. acquired a new stake in Achieve Life Sciences in the second quarter valued at approximately $67,000. Finally, Jane Street Group LLC acquired a new stake in Achieve Life Sciences in the third quarter valued at approximately $53,000. Institutional investors and hedge funds own 21.11% of the company’s stock.
About Achieve Life Sciences
Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Achieve Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Achieve Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.